Oncology pharmacy Onco360 stated on Friday that it will market TAZVERIK (Tazemetostat) for treatment of patients with epithelioid sarcoma under the exclusive specialty pharmacy partnership with Epizyme.
Epizyme added that TAZVERIK (Tazemetostat) is a FDA approved new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Epithelioid sarcoma is a rare, slow-growing subtype of soft tissue sarcoma which occurs primarily in young adults. Greater than 90% of epithelioid sarcoma patients are found to have a genetic mutation, known as loss of INI-1 function, rendering them amenable to treatment with TAZVERIK, a novel EZH2 inhibitor.
In conjunction, TAZVERIK is manufactured by Epizyme, a research-based biotechnology company.
US FDA approval of TAZVERIK is based on the results from Epizyme's open-label, single-arm cohort of patients from the Phase II EZH-202 clinical trial (NCT02601950), which demonstrated a 15% overall rate of response.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval